Alpha Cognition Inc
ACOG
Hisse Senetlerindeki Sıralama
#20417
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Hisse Fiyatı
$8.13
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$126.27M
Değişim (1 gün)
-3.79%
Değişim (1 yıl)
61.63%
Ülke
US
Ticaret Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Alpha Cognition Inc (ACOG) için EPS
June 2026 itibariyle EPS TTM: $-0.40
Alpha Cognition Inc şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-0.40'dir. 2022 yılı sonunda, şirketin EPS'si $-0.18 idi; bu, 2021 yılındaki EPS olan $-0.37 ile önceki yıla göre azalma.
Alpha Cognition Inc için 2018 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $-0.40 | 166.67% |
| 2023 | $-0.15 | -16.67% |
| 2022 | $-0.18 | -51.35% |
| 2021 | $-0.37 | -61.46% |
| 2020 | $-0.96 | 357.14% |
| 2019 | $-0.21 | 672.06% |
| 2018 | $-0.03 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | -4,430.00% |
US
|
|
| $-7.98 | 1,895.00% |
US
|
|
| $-5.29 | 1,222.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,035.00% |
NL
|
